Brief: C4 Therapeutics Expands Long-Term Partnership With Roche Through New Collaboration Agreement Focused On Discovering And Developing Degrader-Antibody Conjugates (DACs)

Roche Holding AG

09/04/2026 12:05

April 9 (Reuters) - C4 Therapeutics, Inc CCCC.O:

C4 THERAPEUTICS EXPANDS LONG-TERM PARTNERSHIP WITH ROCHE THROUGH NEW COLLABORATION AGREEMENT FOCUSED ON DISCOVERING AND DEVELOPING DEGRADER-ANTIBODY CONJUGATES (DACS)

C4 THERAPEUTICS, INC - AGREEMENT COVERS TWO ONCOLOGY TARGETS WITH OPTION FOR THIRD TARGET

C4 THERAPEUTICS, INC - C4T TO RECEIVE ADDITIONAL PAYMENT IF THIRD TARGET OPTION EXERCISED

C4 THERAPEUTICS, INC - C4T TO RECEIVE $20 MILLION UPFRONT

C4 THERAPEUTICS, INC - C4T ELIGIBLE FOR TIERED ROYALTIES ON FUTURE SALES

Source text: ID:nGNX8T6RhB

Further company coverage: CCCC.O

 ((Reuters.Briefs@thomsonreuters.com;))